Lomedeucitinib
Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor[1][2][3].
Product Specifications
CAS Number
[2328068-29-5]
Product Name Alternative
BMS-986322
UNSPSC
12352005
Target
Isotope-Labeled Compounds; JAK
Type
Isotope-Labeled Compounds
Related Pathways
Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Purity
99.75
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=NN=C(NC([C@@H]2CC23CC3)=O)C=C1NC4=NC=CC=C4S(=O)(C)=O)NC([2H])([2H])[2H]
Molecular Formula
C18H17D3N6O4S
Molecular Weight
419.47
References & Citations
[1]Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16 (1) : 111.|[2]Zhang K, et al. Development and therapeutic implications of tyrosine kinase 2 inhibitors[J]. Journal of Medicinal Chemistry, 2023, 66 (7) : 4378-4416.|[3]Andrew Nicholas Billin, et al. Il-31 modulators for treating fxr-induced pruritis. WO2022266444A1. 2022-06-17
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
Phase 2
Isoform
Tyk2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items